Therapeutic eŠects of in vivo gene therapy, which aims to treat diseases by administering therapeutic genes to patients, are obtained via proteins expressed from the gene administered. Therefore, to optimize the therapeutic eŠects of such therapy, it is important to control not only the tissue distribution of gene vectors but also that of proteins expressed from the vector. Studies using protein pharmaceuticals have clearly demonstrated that the therapeutic eŠect depends largely on the spatiotemporal distribution of proteins, such as area under the curve and mean residence time. These results strongly suggest that precise control of the spatiotemporal distribution of proteins increases the e‹cacy of in vivo gene therapy. Based on these considerations, we tried to increase the therapeutic eŠect of plasmid DNA-based gene therapy by controlling the proˆle of proteins expressed form vectors. To increase the residence time of proteins, we developed plasmids with few CpG motifs and achieved sustained expression of proteins at therapeutic levels for as long as several months. Sustained expression of murine interferon g was highly eŠective in inhibiting metastatic tumor growth and atopic dermatitis in mouse models. Thus, designing plasmid vectors is a promising approach not only to controlling the spatiotemporal distribution of proteins, but also to increasing the therapeutic potency of in vivo gene therapy. 
Fire‰y luciferase activity in mouse liver after nonviral gene transfer was plotted against the dose of plasmid expressingˆre‰y luciferase (pCMVLuc). TI, tissue injection of naked plasmid into the liver; EP, electroporation; IV, intravenous injection of naked plasmid; ip, intraportal injection; Gal-pOrn-mHA2 polyplex, galactosylated poly-ornithine-fusogenic peptide/ plasmid complex; Gal-PEI polyplex, galactosylated polyethyleneimine/plasmid complex; Gal-liposome lipoplex, galactosylated cationic liposome/plasmid complex. 
